NCT06066346 - A Study of Talquetamab for People with Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 27, 2023

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions

Multiple Myeloma

Interventions

DRUG

Talquetamab

Talquetamab will be administered SC until disease progression

Trial Locations (7)

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

RECRUITING

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

RECRUITING

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

RECRUITING

Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack

RECRUITING

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale